3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
242
Neoplasms, Plasma Cell
50
Lymphoma
45
Lymphoma, Mantle-Cell
40
Precursor Cell Lymphoblastic Leukemia-Lymphoma
31
Lymphoma, Non-Hodgkin
30
Recurrence
29
Lymphoma, Follicular
24
Leukemia, Myeloid, Acute
24
Lymphoma, Large B-Cell, Diffuse
23
Waldenstrom Macroglobulinemia
22
Lymphoma, B-Cell, Marginal Zone
20
Leukemia
20
Immunoglobulin Light-chain Amyloidosis
18
Leukemia, Lymphocytic, Chronic, B-Cell
14
Myelodysplastic Syndromes
12
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
11
Hodgkin Disease
11
Burkitt Lymphoma
10
Breast Neoplasms
10
Lymphoma, T-Cell, Peripheral
9
Lymphoma, Large-Cell, Anaplastic
9
Lymphoma, B-Cell
9
Lung Neoplasms
9
Immunoblastic Lymphadenopathy
9
Hematologic Neoplasms
9
Prostatic Neoplasms
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, T-Cell
8
Interventions
Docetaxel
4
enzalutamide
3
darolutamide
3
cabazitaxel
3
Pluvicto
3
testosterone 17 beta-cypionate
2
radium Ra 223 dichloride
2
Nivolumab
2
sipuleucel-T
1
rucaparib
1
poly ICLC
1
pamiparib
1
lactitol
1
fludarabine phosphate
1
fludarabine
1
fluciclovine F-18
1
enfortumab vedotin
1
ebastine
1
copanlisib
1
cabozantinib
1
bempegaldesleukin
1
avelumab
1
alovudine
1
abiraterone
1
Standard of Care
1
Single Photon Emission Computed Tomography Computed Tomography
1
Selegiline
1
Radium-223
1
Radiosurgery
1
Radionuclide Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Metastatic Castration-resistant Prostate Cancer
×
Bortezomib
×
Clear all
NCT06029998
2025-11-28
BORXPTEN
University of Utah
Phase 2
Recruiting
22 enrolled